| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bausch Health Companies Inc. | IDP-120 | Acne | Phase 3 | Trial Completed | Topical | N/A |
| Bausch Health Companies Inc. | IDP-120 | Acne | Phase 3 | Trial Completed | Topical | N/A |
| Bausch Health Companies Inc. | NVU-003 (Kalahari) | Dry Eye Disease associated with Meibomian Gland Dysfunction | Phase 3 | Ongoing | Oral | Opthalmic |
| Bausch Health Companies Inc. | Amorphous-Rifaximin SSD - (RED-C) | Prevention of cirrhosis complications | Phase 3 | Data Released | Oral | Gastroenterology |
| Bausch Health Companies Inc. | Amiselimod S1P6 Modulator | Ulcerative Colitis | Phase 3 | Trial Planned | Oral | Gastroenterology |
| Bausch Health Companies Inc. | IDP-124 | Atopic Dermatitis | Phase 3 | Trial Completed | Topical | Immunology |
| Bausch Health Companies Inc. | larsucosterol (DUR-928) - (AHFIRM) | Alcoholic hepatitis (AH) | Phase 3 | Trial Planned | Intravenous | Gastroenterology |
| Bausch Health Companies Inc. | IDP-120 | Acne | Phase 3 | Trial Completed | Topical | N/A |